News

Viewing Page 1 of 1 | Showing Results 1 of 1

One study, multiple immunotherapy combinations for hormone-receptor-positive, HER2-negative breast cancer

April 23, 2018

Women with metastatic hormone-receptor-positive, HER2-negative breast cancer who have progressed after treatment with a CDK4/6 inhibitor may qualify for a newly opened immunotherapy study at Providence Cancer Institute.

Viewing Page 1 of 1 | Showing Results 1 of 1